Primatene Mist Drives Amphastar Sales Growth
Executive Summary
Amphastar reported double-digit growth in the fourth quarter driven by sales of Primatene Mist, epinephrine products and glucagon. The company also revealed that it is anticipating a Q3 FY22 launch of vasopressin.
You may also be interested in...
US Needs OTC Inhalers For Asthma Treatment, And FDA Should Force A Switch, Researchers Say
In addition to epinephrine inhaler indicated for emergency use FDA currently allows for nonprescription access, a “positive step forward would be to make inhaled albuterol available OTC,” say researchers in a recent JAMA article.
Eagle Bags Vasopressin Exclusivity And Details Launch Plans
Generic competition to Vasostrict is nearing in the US after the FDA confirmed Eagle’s previously unresolved potential for 180-day market exclusivity.
Kelix Strikes A Deal To Acquire 14 Oncology Injectables
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.